Corey N. Fishman's most recent trade in Iterum Therapeutics Plc was a trade of 165,226 Subscription Rights (right to buy) done . Disclosure was reported to the exchange on Aug. 6, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 165,226 | 0 | - | - | Subscription Rights (right to buy) | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 82,613 | 82,613 | - | - | Warrants (right to buy) | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 82,613 | 137,062 (0%) | 0% | - | Ordinary Shares | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Aug 2024 | 82,613 | 82,613 | - | - | Warrants (right to buy) | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2023 | 14,333 | 50,132 (0%) | 0% | 0 | Ordinary Shares | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2023 | 14,333 | 0 | - | - | Restricted Share Units | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.96 per share. | 11 Mar 2023 | 5,683 | 44,449 (0%) | 0% | 1.0 | 5,456 | Ordinary Shares |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 215,000 | 215,000 | - | - | Restricted Share Units | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 215,000 | 537,008 (3%) | 1% | - | Ordinary Shares | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2021 | 5,280,000 | 5,280,000 | - | - | Stock Option (Right to Buy) | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Mar 2021 | 430,000 | 430,000 | - | - | Restricted Share Units | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2021 | 167,500 | 407,453 (2%) | 1% | 0 | Ordinary Shares | |
| Iterum Therapeutics Plc | Corey N. Fishman | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 1.73 per share. | 25 Jan 2021 | 85,445 | 322,008 (2%) | 0% | 1.7 | 147,820 | Ordinary Shares |